Gene:
ITGB3
integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs5918 10634882T>C, 176T>C, 34523T>C, 45360730T>C, A2, GP IIIa HPA-1, GP3A PIA2, HPA-1b, ITGB3:1565T>C, ITGB3:Leu33Pro, Leu33Pro polymorphism of ß3 integrins, Leu59Pro, P1A2, PI, PIA1/PIA2
T > C
Missense
Leu59Pro
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  platelet glycoprotein IIIa
Alternate Symbols:  CD61; GPIIIa
PharmGKB Accession Id: PA205

Details

Cytogenetic Location: chr17 : q21.32 - q21.32
GP mRNA Boundary: chr17 : 45331208 - 45390077
GP Gene Boundary: chr17 : 45321208 - 45393077
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Platelet Aggregation Inhibitor Pathway, Pharmacodynamics
    Effects of antiplatelet drugs on platelet aggregation pathway.
  1. VEGF Signaling Pathway
    Model endothelial cell displaying genes of the VEGF signalling pathway and the sites at which bevacizumab, sorafenib, sunitinib, brivanib and cilengitide are known to act.

External Pathways

Links to non-PharmGKB pathways.

  1. Arf6 signaling events - (Pathway Interaction Database NCI-Nature Curated)
  2. Ephrin B reverse signaling - (Pathway Interaction Database NCI-Nature Curated)
  3. Exocytosis of Alpha granule - (Reactome via Pathway Interaction Database)
  4. Grb2:SOS provides linkage to MAPK signaling for Intergrins - (Reactome via Pathway Interaction Database)
  5. IL4-mediated signaling events - (Pathway Interaction Database NCI-Nature Curated)
  6. Integrin alphaIIbbeta3 signaling - (Reactome via Pathway Interaction Database)
  7. Integrin cell surface interactions - (Reactome via Pathway Interaction Database)
  8. Integrins in angiogenesis - (Pathway Interaction Database NCI-Nature Curated)
  9. Nectin adhesion pathway - (Pathway Interaction Database NCI-Nature Curated)
  10. Osteopontin-mediated events - (Pathway Interaction Database NCI-Nature Curated)
  11. p130Cas linkage to MAPK signaling for integrins - (Reactome via Pathway Interaction Database)
  12. PECAM1 interactions - (Reactome via Pathway Interaction Database)
  13. phospholipids as signalling intermediaries - (BioCarta via Pathway Interaction Database)
  14. Platelet Aggregation (Plug Formation) - (Reactome via Pathway Interaction Database)
  15. Plug Formation - (Reactome via Pathway Interaction Database)
  16. Signaling events mediated by PTP1B - (Pathway Interaction Database NCI-Nature Curated)
  17. Signaling events mediated by VEGFR1 and VEGFR2 - (Pathway Interaction Database NCI-Nature Curated)
No related genes are available

Curated Information ?

Curated Information ?

Publications related to ITGB3: 29

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis. British journal of clinical pharmacology. 2014. Floyd Christopher N, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA : the journal of the American Medical Association. 2011. Cayla Guillaume, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of osteoporosis-related bone fractures: moving towards the harmonization and validation of polymorphism diagnostic tools. Pharmacogenomics. 2010. Rojo Venegas Karen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Platelet pharmacogenomics. Journal of thrombosis and haemostasis : JTH. 2010. Zuern C S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin. Thrombosis research. 2010. Abderrazek Fatma, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics in cardiovascular antithrombotic therapy. Journal of the American College of Cardiology. 2009. Marín Francisco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Assessing the reproducibility of asthma candidate gene associations, using genome-wide data. American journal of respiratory and critical care medicine. 2009. Rogers Angela J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2009. Motovska Zuzana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic determinants of response to clopidogrel and cardiovascular events. The New England journal of medicine. 2009. Simon Tabassome, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inherited traits affecting platelet function. Blood reviews. 2008. Salles Isabelle I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Platelet genomics and the risk of atherothrombosis. Journal of thrombosis and haemostasis : JTH. 2007. Ouwehand W H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk. Journal of medical genetics. 2007. Jakubowska Anna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics. 2007. Li Qing, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Dose-related efficacy of aspirin after coronary surgery in patients With Pl(A2) polymorphism (NCT00262275). The Annals of thoracic surgery. 2007. Lim Eric, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thrombosis research. 2007. Lev Eli I, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease. Thrombosis research. 2007. Dropinski Jerzy, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. Journal of the American College of Cardiology. 2006. Cooke Glen E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thrombosis and haemostasis. 2006. Lepäntalo Aino, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism. The Journal of thoracic and cardiovascular surgery. 2005. Morawski W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation?. The Annals of pharmacotherapy. 2005. Papp Elod, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2004. Angiolillo Dominick J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Platelet PlA2 polymorphism and platelet activation are associated with increased troponin I release after cardiopulmonary bypass. Anesthesiology. 2002. Rinder Christine S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood. 2001. O'Connor F F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation. 2001. Undas A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. The American journal of cardiology. 2001. Bray P F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. British journal of haematology. 2000. Szczeklik A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation. 2000. Michelson A D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet. 1999. Undas A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 1997. Walter D H, et al. PubMed

LinkOuts

Entrez Gene:
3690
OMIM:
173470
UCSC Genome Browser:
NM_000212
RefSeq RNA:
NM_000212
RefSeq Protein:
NP_000203
RefSeq DNA:
AC_000060
AC_000149
NC_000017
NG_008332
NT_010783
NW_001838448
NW_926883
UniProtKB:
ITB3_HUMAN (P05106)
Ensembl:
ENSG00000056345
ENSG00000259753
GenAtlas:
ITGB3
GeneCard:
ITGB3
MutDB:
ITGB3
ALFRED:
LO000611I
LO011212H
HuGE:
ITGB3
Comparative Toxicogenomics Database:
3690
ModBase:
P05106
HumanCyc Gene:
HS00694
HGNC:
6156

Common Searches